TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7683447
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml hydroxyethyl starch (HAES)
Study: 7683447
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml NaCl 0.9%
Study: 12952113
Drug: Omalizumab (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omalizumab (administered every 2 or 4 weeks for 52 weeks)
Study: 12952113
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered for 28 weeks)
Study: 10543320
Drug: Hydroxyurea plus
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea plus didanosine (ddI) at a dosage of 500 mg twice a day for at least 40 weeks
Study: 7776857
Drug: Interferon‐a2b subcutaneously
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon‐a2b subcutaneously three times weekly for 12 months (5 MU/m2 for 4 months and then 3 MU/m2 for a further 8 months)
Study: 7472292
Drug: Anorexigenic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anorexigenic drugs (phenmetrazine)
Study: 7472292
Drug: Anorexigenic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anorexigenic drugs (phentermine)
Study: 7472292
Drug: Anorexigenic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anorexigenic drugs (mazindol)
Study: 30249203
Drug: Self-management (includes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-management (includes educational components, SMBP, and self-titration of antihypertensive medication)
Study: 27481309
Drug: Brodalumab 350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brodalumab 350 mg
Study: 27481309
Drug: Brodalumab 700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brodalumab 700 mg
Study: 26769445
Drug: Enhanced Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced Cognitive Behavioural Therapy (CBT‐E)
Study: 26769445
Drug: Maudsley Anorexia
Normalized name: phendimetrazine tartrate Extended Release Oral Capsule [Anorex]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maudsley Anorexia Nervosa Treatment for Adults (MANTRA)
Study: 23846733
Drug: Metformin (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1,000 mg twice daily for 16 weeks)
Study: 21120259
Drug: Topical keratolytic
Normalized name: KERATOLYTICS/CAUSTICS,TOPICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical keratolytic treatment
Study: 15963095
Drug: Fluvoxamine, 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine, 25 mg twice daily for 6 days
Study: 1834765
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose Lorazepam (LOR)
Study: 1834765
Drug: Neither drug
Normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neither drug (LOR or SCOP)
Study: 17584562
Drug: Nebivolol 5
Normalized name: nebivolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol 5 mg (medium dose)
Study: 17584562
Drug: Nebivolol low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol low dose (1.25 or 2.5 mg)
Study: 15464768
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose oxytocin (4.5 microm/min initially, increased by 4.5 microm/min every 30 min)
Study: 15464768
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose oxytocin (1.5 microm/min initially, increased by 1.5 microm/min every 30 min)
Study: 11374116
Drug: Creatine (Cr)
DrugBank: Creatine (DB00148)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Creatine (Cr) supplementation (5 g of Cr and 5 g maltodextrin four times a day for 5 days)
Study: 11374116
Drug: Placebo (P)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (P) supplementation (5 g of maltodextrin four times a day for 5 days)
Study: 7863015
Drug: Moderate and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate and high doses of alcohol
Study: 7863015
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of diazepam
Study: 7863015
Drug: Baseline and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline and treatment conditions
Study: 949688
Drug: Oral methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral methotrexate plus radiation
Study: 949688
Drug: Intravenous methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous methotrexate plus radiation
Study: 30382188
Drug: Baclofen (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (30 mg/d)
Study: 31079155
Drug: Bioabsorbable polymer
Normalized name: dicresulene polymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioabsorbable polymer drug-eluting stents (BP-DES)
Study: 25310347
Drug: Topical dexamethasone
Normalized name: dexamethasone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical dexamethasone 0.1%/povidone‐iodine 0.4% eye drops four times daily for seven days
Study: 25310347
Drug: Artificial tears
Normalized name: Artificial Tears
DrugBank: Polyethylene glycol 400 (DB11077)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artificial tears four times daily for seven days
Study: 25310347
Drug: Topical dexamethasone
Normalized name: dexamethasone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical dexamethasone 0.1%/povidone‐iodine 0.4% eye drops
Study: 21565956
Drug: Free oral
Normalized name: CariFree Oral Paste Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free oral hydration (Group A)
Study: 21565956
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of 10 mg of furosemide and infusion of 500 mL of saline solution starting 5 min after tracer injection (Group B)
Study: 21565956
Drug: Oral hydration
Normalized name: terpin hydrate Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hydration with 500 mL of water (Group C)
Study: 21565956
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of 10 mg of furosemide and infusion of 250 mL of saline solution starting 30 min after (18)F‐FDG injection (Group D)
Study: 18651888
Drug: 2% xylocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% xylocaine gel
Study: 12830441
Drug: Conventional thrice-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional thrice-weekly HD (Control)
Study: 11296178
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg once daily for five doses
Study: 11296178
Drug: Levofloxacin 750
Normalized name: levofloxacin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 750 mg once daily for five doses
Study: 11296178
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg q12h for nine doses
Study: 8779455
Drug: Piperacillin, 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin, 4 g, given intravenously approximately 30 minutes before ERCP
Study: 20525705
Drug: torasemide 5
Normalized name: Torasemide 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: torasemide 5 mg daily
Study: 16238799
Drug: Standardized unmodified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized unmodified extract (Group A), maximum concentration of 308.5 mcg/mL, 11 injections total.
Study: 16238799
Drug: Standardized modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized modified allergen extract (Group B), maximum concentration of 2400 mcg/mL, 11 injections total.
Study: 7892535
Drug: 10 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml/kg of Ringer solution (low dose crystalloid group)
Study: 7892535
Drug: 20 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml/kg of Ringer solution (high dose crystalloid group)
Study: 7892535
Drug: 10 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml/kg of Ringer solution with 10 ml/kg of hydroxi‐ethyl‐almidon solution (group C‐HEA)
Study: 582393
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg viloxazin
Study: 6896312
Drug: Coke (360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coke (360 ml)
Study: 6896312
Drug: Tab (360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tab (360 ml)
Study: 6896312
Drug: Instant Maxwell
Normalized name: Advanced Eye Relief Redness Instant Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instant Maxwell House coffee (4.5 g)
Study: 6896312
Drug: Instant Kava
Normalized name: KAVA
DrugBank: Kava (DB01322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instant Kava coffee (4.5 g)
Study: 6896312
Drug: Instant Sanka
Normalized name: Advanced Eye Relief Redness Instant Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instant Sanka coffee (4.5 g)
Study: 6896312
Drug: Tea (4.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tea (4.25 g)
Study: 6896312
Drug: Beer (360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beer (360 ml)
Study: 6896312
Drug: Milk (360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk (360 ml)
Study: 30792154
Drug: Metformin (pooled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (pooled analysis)
Study: 30565556
Drug: Group 'A'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 'A' (discontinued treatment)
Study: 30565556
Drug: Group 'NA'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 'NA' (completed treatment)
Study: 22232305
Drug: Oral sucrose
Normalized name: TootSweet 24% Oral Sucrose Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sucrose (0.2 mL/kg)
Study: 22232305
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of FT and sucrose
Study: 21125792
Drug: Shuanghuangbu-scaffold extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shuanghuangbu-scaffold extract at 100 microg x mL(-1)
Study: 7714108
Drug: IL-1 receptor
Normalized name: IL-1 TRAP
DrugBank: Rilonacept (DB06372)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-1 receptor antagonist (IL-1ra) alone (133 mg/h)
Study: 26319082
Drug: Mammaplasty group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mammaplasty group (MG)
Study: 19106252
Drug: Standardized functional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized functional physical and occupational therapies for 6 months (PT/OT group)
Study: 19106252
Drug: Standardized functional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized functional physical and occupational therapies for 6 months plus multimuscle BTX‐A (BTX+ group)
Study: 9084574
Drug: meloxicam 7.5
Normalized name: meloxicam 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: meloxicam 7.5 mg per day for 6 days
Study: 9084574
Drug: indomethacin 25
Normalized name: indomethacin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: indomethacin 25 mg three times per day for 3 days
Study: 3490684
Drug: Norfloxacin 400
Normalized name: norfloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin 400 mg twice daily for 4 to 6 weeks
Study: 3490684
Drug: Co-trimoxazole 160/800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole 160/800 mg twice daily for 4 to 6 weeks
Study: 23061785
Drug: Low-dose ketamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ketamine (loading dose 0.25 mg·kg(‐1), infusion 10-20 μg·kg(‐1)·min(‐1))
Study: 23061785
Drug: Midazolam (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (loading dose 0.02 mg·kg(‐1), infusion 1-2 μg·kg(‐1)·min(‐1))
Study: 17058231
Drug: Gabapentin (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (starting dose of 300 mg orally per day, max 2,400 mg)
Study: 12629464
Drug: HMBCr (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMBCr (3 g/d HMB + 3 g/d Cr)
Study: 8680887
Drug: Aerosolized pentamidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized pentamidine (AP) 60 mg every 2 weeks
Study: 8680887
Drug: Aerosolized pentamidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized pentamidine (AP) 120 mg every 4 weeks
Study: 6344677
Drug: Dihydroergotamine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergotamine and heparin (0.5 mg dihydroergotamine plus 5,000 units of heparin administered twice daily)
Study: 6344677
Drug: Heparin (5,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (5,000 units administered three times daily)
Study: 22682335
Drug: Leucodepleted buffy-coat
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leucodepleted buffy-coat platelet pools prepared in additive solution
Study: 18069511
Drug: 14% hydrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14% hydrogen peroxide whitening strips used for 30 minutes twice daily for 14 days
Study: 10468703
Drug: Ranitidine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (both doses)
Study: 7604669
Drug: Rectal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal saline infusion test
Study: 7604669
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of routine anal manometry, rectal saline infusion test, and balloon-retaining test
Study: 7604669
Drug: Balloon-retaining test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balloon-retaining test vs. rectal saline infusion test
Study: 18375082
Drug: Diazepam (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (mean dose 12.7 mg)
Study: 18375082
Drug: Midazolam (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (mean dose 3.9 mg) and Fentanyl (mean dose 108 mcg)
Study: 1424420
Drug: Zidovudine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (200 mg every 4 hours while awake) and naproxen (500 mg every 12 hours for 4 days)
Study: 1424420
Drug: Zidovudine alone
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine alone (200 mg every 4 hours while awake)
Study: 2869950
Drug: Cholinergic agonists
Normalized name: PARASYMPATHOMIMETICS (CHOLINERGICS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholinergic agonists
Study: 31526169
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g aminocaproic acid in 200 mL saline
Study: 31526169
Drug: 200 mL
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mL normal saline
Study: 20571249
Drug: pre-treatment with
Approvals — FDA: no, EMA: no, PMDA: no
Description: pre-treatment with tissue-type plasminogen activator (t-PA) combined with back-up of facilitated PCI
Study: 15618381
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of radiography and MR imaging
Study: 8636522
Drug: Intratracheal, humidified,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratracheal, humidified, O2‐mixture insufflation (TGI) at 3 l/min
Study: 8636522
Drug: Intratracheal, humidified,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratracheal, humidified, O2‐mixture insufflation (TGI) at 6 l/min
Study: 2192529
Drug: Antihypertensive medication
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive medication for 3 months
Study: 26066385
Drug: Subfascial injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subfascial injection of local anesthetic (Gp SF)
Study: 26066385
Drug: Extrafascial injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extrafascial injection of local anesthetic (Gp EF)
Study: 20031771
Drug: Stenting of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stenting of the main branch (MB, Taxus‐stent, paclitaxel‐eluting stents) and mandatory side branch (SB) PCI (kissing balloons) with provisional SB stenting (therapy A)
Study: 20031771
Drug: Stenting of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stenting of the MB (paclitaxel‐eluting stents) with provisional SB-PCI only when SB had TIMI flow <2 (therapy B)
Study: 18036082
Drug: Prolonged-release melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release melatonin 2 mg (PR-melatonin)
Study: 15560843
Drug: Intensive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive group training protocol combining exercise therapy with principles of behavioural therapy and back school
Study: 3145064
Drug: 125I labelled
Normalized name: fibrinogen (125I)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125I labelled soluble human insulin (0.05 U/kg)
Study: 3145064
Drug: Insulin analogue
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin analogue (0.05 U/kg)
Study: 3145064
Drug: 125I labelled
Normalized name: fibrinogen (125I)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125I labelled soluble human insulin (0.1 U/kg)
Study: 3145064
Drug: Insulin analogue
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin analogue (0.1 U/kg)
Study: 3145064
Drug: Soluble insulin
Normalized name: Soluble insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Soluble insulin (0.05 U/kg)
Study: 3145064
Drug: Soluble insulin
Normalized name: Soluble insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Soluble insulin (0.1 U/kg)
Study: 29862411
Drug: everolimus plus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: everolimus plus exemestane (10 mg/d + 25 mg/d)
Study: 29862411
Drug: everolimus alone
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: everolimus alone (10 mg/d)
Study: 29862411
Drug: capecitabine alone
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: capecitabine alone (1250 mg/m2 twice daily)
Study: 23306596
Drug: Incredible Years
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incredible Years Toddler Parenting Program (12 sessions) under research contexts (with weekly supervision)
Study: 18947487
Drug: GOS-formula feeding
Approvals — FDA: no, EMA: no, PMDA: no
Description: GOS-formula feeding (2.4 g/L)
Study: 15843764
Drug: Reboxetine at
Normalized name: REBOXETINE
DrugBank: Reboxetine (DB00234)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reboxetine at a dose of 4 mg/day
Study: 12592082
Drug: Bexarotene (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bexarotene (oral or topical gel)
Study: 10470423
Drug: 5-FU 450
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU 450 mg/m2 plus Levamisol (B)
Study: 10470423
Drug: 5-FU 600
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU 600 mg/m2 (C)
Study: 8767614
Drug: Propafenone 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone 450 mg as single dose followed by 300 mg t.i.d.
Study: 8767614
Drug: Hydroquinidine 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroquinidine 900 mg/24 hours + digoxin if necessary
Study: 1826073
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg morphine (group B)
Study: 1826073
Drug: 30 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 micrograms sufentanil plus 3 mg morphine (group C)
Study: 6991534
Drug: Proquazone (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proquazone (300 mg)
Study: 6991534
Drug: New formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: New formulations of analgesic combinations (aminophenazone replaced by propyphenazone)
Study: 6991534
Drug: Aspirin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (250 mg)
Study: 6991534
Drug: Aspirin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (1000 mg) vs Placebo
Study: 30589607
Drug: Salbutamol nebulization
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol nebulization (5 mg)
Study: 28222149
Drug: Praziquantel treatment
Normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Praziquantel treatment (20, 40, and 60 mg/kg)
Study: 25887550
Drug: Multimodal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal treatment (MMT) including neurophysiological education, sensory training, and motor training, with up to 16 sessions over 8 to 12 weeks and additional home training of 10 to 30 minutes five times per week.
Study: 25887550
Drug: Usual physiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Usual physiotherapy treatment (UPT), with up to 16 sessions over 8 to 12 weeks and additional home training of 10 to 30 minutes five times per week.
Study: 25887550
Drug: Multimodal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal treatment (MMT)
Study: 25887550
Drug: Usual physiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Usual physiotherapy treatment (UPT)
Study: 19636365
Drug: Pentavalent antimony
Normalized name: Pentavalent Antimony
DrugBank: Pentavalent Antimony (DB13047)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentavalent antimony plus 5% imiquimod cream applied to each lesion three times per week for 20 days
Study: 19636365
Drug: Pentavalent antimony
Normalized name: Pentavalent Antimony
DrugBank: Pentavalent Antimony (DB13047)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentavalent antimony plus placebo (vehicle cream) applied as above
Study: 16454145
Drug: Zinc gluconate
Normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc gluconate nasal spray (10 mmol)
Study: 11410114
Drug: Lisinopril 20
Normalized name: lisinopril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 20 mg for 8 weeks
Study: 7686216
Drug: Cisplatin 100
Normalized name: CISPLATIN 100MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m2 IV day 1 and Vinblastine 6 mg/m2 IV days 1 and 2 every 3 weeks (PV)
Study: 7686216
Drug: Cisplatin 100
Normalized name: CISPLATIN 100MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m2 IV day 1 and Vinblastine 6 mg/m2 IV days 1 and 2 every 3 weeks with Bleomycin 30 mg IM weekly (PVB)